Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

More work on the way for W0101
July 2018
SHARING OPTIONS:

CASTRES, France—Mid-May saw an extension of the collaboration between Pierre Fabre and Roche to develop a companion diagnostic (CDx) for W0101. The partnership now extends from developing a prototype immunohistochemistry assay as a CDx for W0101 to include the retrospective determination of IGF-1R expression in patients enrolled in a Phase 1/2 clinical study of the compound. W0101 is an antibody-drug conjugate product candidate that targets the insulin-like growth factor 1 (IGF-1) receptor, and is presently being evaluated in a Phase 1/2 clinical study in patients with relapsed/refractory solid tumors.
 
“It is noteworthy that the IGR-1R antibody used in the diagnostic assay binds a different epitope than the antibody from the therapeutic construct, both developed by Pierre Fabre Research Institute,” said Dr. Alexandre Passioukov, vice president of translational medicine at Pierre Fabre Research Institute.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.